EP3983412A4 - PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF - Google Patents
PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF Download PDFInfo
- Publication number
- EP3983412A4 EP3983412A4 EP20821692.9A EP20821692A EP3983412A4 EP 3983412 A4 EP3983412 A4 EP 3983412A4 EP 20821692 A EP20821692 A EP 20821692A EP 3983412 A4 EP3983412 A4 EP 3983412A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- prostaglandin
- antagonists
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101150109738 Ptger4 gene Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962859924P | 2019-06-11 | 2019-06-11 | |
| PCT/US2020/036852 WO2020251957A1 (en) | 2019-06-11 | 2020-06-09 | Prostaglandin e2 receptor 4 antagonists and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3983412A1 EP3983412A1 (en) | 2022-04-20 |
| EP3983412A4 true EP3983412A4 (en) | 2023-12-27 |
Family
ID=73781536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20821692.9A Withdrawn EP3983412A4 (en) | 2019-06-11 | 2020-06-09 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220324803A1 (en) |
| EP (1) | EP3983412A4 (en) |
| JP (1) | JP2022536607A (en) |
| CN (1) | CN114206866A (en) |
| WO (1) | WO2020251957A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007143825A1 (en) * | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
| WO2015094902A1 (en) * | 2013-12-17 | 2015-06-25 | Eli Lilly And Company | Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators |
| EP2422779B1 (en) * | 2009-04-22 | 2016-01-06 | RaQualia Pharma Inc. | Selective ep4 receptor antagonistic substance for treatment of cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101284773A (en) * | 2001-08-09 | 2008-10-15 | 小野药品工业株式会社 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| ES2392192T3 (en) * | 2006-04-24 | 2012-12-05 | Merck Canada Inc. | Indole amide derivatives as EP4 receptor antagonists |
| JP5408434B2 (en) * | 2007-07-03 | 2014-02-05 | アステラス製薬株式会社 | Amide compounds |
| EP2565191B1 (en) * | 2008-05-14 | 2014-10-08 | Astellas Pharma Inc. | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy |
| JP5536773B2 (en) * | 2008-08-14 | 2014-07-02 | ベータ・ファーマ・カナダ・インコーポレイテッド | Heterocyclic amide derivatives as EP4 receptor antagonists |
| WO2015188051A1 (en) * | 2014-06-06 | 2015-12-10 | Biogen Ma Inc. | Atx modulating agents |
| WO2018195123A1 (en) * | 2017-04-18 | 2018-10-25 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| CN111727044A (en) * | 2018-02-05 | 2020-09-29 | 深圳市原力生命科学有限公司 | Heterobicyclic Carboxylic Acids for the Treatment of Cancer or Inflammatory Diseases |
| US12240812B2 (en) * | 2019-01-22 | 2025-03-04 | Keythera (Suzhou) Pharmaceuticals Co. Ltd. | Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof |
| CN112608271A (en) * | 2020-11-26 | 2021-04-06 | 安润医药科技(苏州)有限公司 | Amide derivatives and their use in the preparation of EP4 receptor antagonists |
-
2020
- 2020-06-09 WO PCT/US2020/036852 patent/WO2020251957A1/en not_active Ceased
- 2020-06-09 JP JP2021569220A patent/JP2022536607A/en not_active Withdrawn
- 2020-06-09 US US17/615,821 patent/US20220324803A1/en not_active Abandoned
- 2020-06-09 EP EP20821692.9A patent/EP3983412A4/en not_active Withdrawn
- 2020-06-09 CN CN202080052433.5A patent/CN114206866A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007143825A1 (en) * | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
| EP2422779B1 (en) * | 2009-04-22 | 2016-01-06 | RaQualia Pharma Inc. | Selective ep4 receptor antagonistic substance for treatment of cancer |
| WO2015094902A1 (en) * | 2013-12-17 | 2015-06-25 | Eli Lilly And Company | Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2020251957A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220324803A1 (en) | 2022-10-13 |
| JP2022536607A (en) | 2022-08-18 |
| EP3983412A1 (en) | 2022-04-20 |
| WO2020251957A1 (en) | 2020-12-17 |
| CN114206866A (en) | 2022-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3762380T (en) | PHENYLPYROLIDINONE FORMILPEPTIDO 2 RECEPTOR ANTAGONISTS | |
| EP4054583A4 (en) | MELANOCORTIN SUBTYPE 2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | |
| IL292692A (en) | mrgprx2 antagonists and their uses | |
| EP3697759A4 (en) | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS | |
| EP3978528A4 (en) | INTERLEUKIN-4 RECEPTOR ANTIBODIES AND THEIR USE | |
| EP3860977A4 (en) | INTEGRIN ANTAGONISTS | |
| IL285626A (en) | Claudin 6 antibodies and their uses | |
| EP4081525C0 (en) | Antagonists of the spirocyclic piperidine melanocortin subtype 2 receptor (MC2R) and their uses | |
| EP3938401A4 (en) | ANTI-BCMA CHEMICAL ANTIGEN RECEPTORS | |
| EP3802500A4 (en) | MELANOCORTIN SUBTYPE 2 RECEPTOR (MC2R) ANTAGONISTS AND THEIR USES | |
| EP3703680A4 (en) | MUSCARIN M4 ACETYLCHOLINE RECEPTOR ANTAGONISTS | |
| EP3807318A4 (en) | MULTI-SPECIFIC ANTIBODY CONSTRUCTIONS | |
| EP4071172A4 (en) | ANTI-LILRB1 ANTIBODIES AND USES THEREOF | |
| EP3651762A4 (en) | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS | |
| IL292693A (en) | mrgprx2 antagonists and their uses | |
| EP3746421A4 (en) | MUSCARIN ACETYLCHOLIN M4 RECEPTOR ANTAGONISTS | |
| EP3823978A4 (en) | ANTI-CRNF ANTIBODY COMPOSITIONS | |
| MA54052A (en) | ANTIBODY FORMULATION | |
| IL286696A (en) | Human anti-claudin 18.2 chimeric antigen receptors and uses thereof | |
| MA53218A (en) | INTEGRIN ANTAGONISTS | |
| EP3654982A4 (en) | 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES | |
| EP3723787A4 (en) | DARIC INTERLEUKIN RECEPTORS | |
| MA54139A (en) | ANTIBODY FORMULATION | |
| EP3894441A4 (en) | RANK ANTAGONISTS AND THEIR USES | |
| EP3762386A4 (en) | ADENOSINE RECEPTOR ANTAGONISTS AND THEIR USES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20211201 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40073517 Country of ref document: HK |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230511 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20231124 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 209/42 20060101ALI20231120BHEP Ipc: A61P 35/00 20060101ALI20231120BHEP Ipc: A61K 31/4045 20060101ALI20231120BHEP Ipc: A61K 31/416 20060101ALI20231120BHEP Ipc: A61K 31/472 20060101ALI20231120BHEP Ipc: A61K 31/437 20060101ALI20231120BHEP Ipc: C07D 209/20 20060101ALI20231120BHEP Ipc: C07D 231/56 20060101ALI20231120BHEP Ipc: C07D 471/04 20060101AFI20231120BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20240613 |